5 Minutes Read

Adar Poonawalla will buy London’s most expensive house of 2023 for £138 million

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The 42-year old Indian billionaire will pay £138 million for the nearly a century old Aberconway House near Hyde Park.

Adar Poonawalla, CEO of Serum Institute of India’s (SII), which makes the Covishield vaccine, has closed a deal to buy the most expensive home to be sold in London this year.

The 42-year old Indian billionaire will pay £138 million for the nearly a century old Aberconway House near Hyde Park, according to reports.

CNBC-TV18 has independently confirmed the deal. “It is a company guest house which is useful for hosting events donors tech partners and it has helped serum group in accessing global opportunities that were not possible to do from India,” sources said.

The property will be acquired by Serum Life Sciences, a UK subsidiary of the Poonawalla family’s Serum Institute of India. This deal will make Aberconway House the second-most expensive home ever sold in London.

The priciest residential transaction in London occurred in January 2020 when 2-8a Rutland Gate was sold for a record-breaking £210 million. Originally, attributed to the estate of the former Saudi Arabian crown prince Sultan bin Abdulaziz, recent revelations disclosed that the actual buyer was Hui Ka Yan, the founder and chair of Evergrande.

 

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Serum Institute’s BCG vaccine approved by Indian govt for bladder cancer treatment in Canada

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The Indian government approved the export of BCG vaccine from Serum Institute to Canada for bladder cancer immunotherapy. BCG is a freeze-dried preparation derived from Mycobacterium bovis and is administered directly into the bladder lining.

According to official sources, the government has granted approval for the export of the BCG vaccine, produced by the Serum Institute of India, to Canada.

The purpose of this export is to utilise the vaccine for immunotherapy in the treatment of bladder cancer.

The permission was sought by Prakash Kumar Singh, the director of the Serum Institute, who reached out to the Drugs Controller of India (DCGI) for the necessary approval.

BCG, in its capacity as an immunotherapy, is a freeze-dried preparation derived from a weakened strain of Mycobacterium bovis, commonly known as Bacillus Calmette Guerin.

The Serum Institute offers this product in two presentations: 40 mg and 80 mg.

The immunotherapy involves intravesical instillation, where the vaccine is administered directly into the bladder using a catheter.

It remains in the bladder lining for a specific duration, effectively targeting cancer cells without causing harm to other parts of the body.

The vaccine is also used to treat tuberculosis in humans. According to the World Health Organisation, it is used in countries with a high prevalence of TB to prevent childhood tuberculous meningitis and miliary disease.

Earlier in April this year, Venus Pharma GmbH, the company’s German subsidiary, secured marketing authorisation from the UK for Cisplatin, a chemotherapy drug used as a first-line treatment for advanced ovarian cancer, testicular cancer and bladder carcinoma.

With agency inputs.

 

 

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Serum Institute of India resumes Covishield manufacturing, encourages adults to take booster shot

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Poonawalla stressed that there is enough stock of vaccines available from all manufacturers, but the demand for vaccines is currently low. He urged private citizens, especially the elderly, to take the booster shot as a precautionary measure against the Omicron and XBB variants of the virus.

Amidst rising COVID-19 cases in India, Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday announced the resumption of manufacturing of the Covishield vaccine, which had been paused since December 2021.

Poonawalla has also encouraged adults to take the Covovax booster shot, stating that SII has already manufactured six million doses of the vaccine.

Poonawalla stressed that there is enough stock of vaccines available from all manufacturers, but the demand for vaccines is currently low. He urged private citizens, especially the elderly, to take the booster shot as a precautionary measure against the Omicron and XBB variants of the virus.

According to Poonawalla, Covovax is the best booster to take as it has excellent neutralising antibodies.

Also read: AIIMS-Delhi issues advisory after staff tests positive for COVID-19

SII plans to make 6-7 million doses of Covishield available in the next 90 days, and it may take up to nine months to build up stock based on demand.

The company had stopped manufacturing of Covishield in December 2021.

The Covovax vaccine has been approved as a booster dose for adults aged 18 years and above, and it is available on the CoWin app.

Poonawalla reiterated that people need to come to the vaccination centers to get the booster dose and pay for it. He emphasised that if the demand does not increase, hospitals will not put orders on manufacturers, and there will be no stock available.

“There is no demand…that’s why there is no stock with the hospitals. It is not that the vaccine manufacturers are not interested in making it. We’re interested in making it, if of course the demand is there. That’s a normal standard practice.”

Also read: India sees big spike in COVID cases with over 10,000 new infections

“The point I’m trying to make is that the private citizens, who should mask up, and the elderly, especially should come in and pick up the precautionary dose. They have to come and pay for it. They have to pay Rs 225 for the vaccine plus Rs 150 or Rs 200 for the administration charges.”

“If that does not happen, there will not be demand from the hospitals to put orders on manufacturers.”

With inputs from PTI

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Indian Business Leaders Awards 2023: Meet this year’s power-packed jury

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The CNBC-TV18 India Business Leader Awards (IBLA), India’s most coveted award for business excellence turns 18 this year. The IBLA Jury meet was held on February 8, 2023. During the event, the business leaders held discussion on the theme, ‘India @2023: Resilience to Resurgence’ after the jury deliberations.

The CNBC-TV18 India Business Leader Awards (IBLA), India’s most coveted awards for business excellence, turns 18 this year. The IBLA Jury was held on February 8. During the event, the business leaders held a discussion on the theme ‘India @2023: Resilience to Resurgence’ after the jury deliberation.

Tag along as we discuss in detail who these jury members are, and where they stand in the business world.

Jury Chairman: Aditya Birla Group Chairman Kumar Mangalam Birla

Billionaire industrialist and Chairman of Aditya Birla Group Kumar Mangalam Birla heads one of the largest global conglomerates in India. He chairs the boards of all major group companies including Hindalco Industries, Grasim Industries, UltraTech Cement, Aditya Birla Fashion and Retail and Aditya Birla Capital.

The 55-year-old billionaire was named one of the nine recipients of the Padma Bhushan — India’s third highest civilian award — this year, for his contribution to the field of trade and industry.

According to Forbes India’s Richest 100 list of 2022, Birla sits in the 9th spot with an estimated net worth of $15 billion.

Birla took over as the chairman of the Aditya Birla Group in 1995. and during his tenure, the the group’s annual turnover has increased from $2 billion in 1995 to $45 billion in 2021. Today, the group is present in 36 countries across six continents with over 50 percent of its revenues coming from overseas operations.

Uday Kotak, Managing Director, Kotak Mahindra Bank

Uday Kotak is the executive vice-chairman and managing director of Kotak Mahindra Bank. Kotak was ranked 12th in the Forbes’ list of India’s Richest in 2022. With an estimated valuation of $13.3 billion, Kotak Mahindra Bank is now among India’s top four banks in the private sector, boosted by its 2014 acquisition of ING Bank’s Indian operations.

India Today magazine ranked Kotak 8th in India’s 50 most powerful people of 2017 list. In August 2019, he was reported to be one of the most highly paid CEOs of any Indian bank with a monthly salary of Rs 27 lakh.

Zarin Daruwala, Cluster CEO, India and South Asia Markets, Standard Chartered Bank 

Zarin Daruwala became the first female CEO of Standard Chartered Bank in 2016. She began her career over 30 years ago with the ICICI Group where she spent 26 years of her career, starting out as a management trainee, eventually becoming President and Head of the Wholesale Banking business. 

After she took over the role of Cluster CEO of India and South Asia Markets at Standard Chartered Bank, she has brought the company back from the brink of financial ruin. With an experience of over 30 years, she has worked across all areas of banking ranging from wholesale banking, agri-finance, corporate finance, corporate planning, investment banking and credit.

Daruwala was selected seven times as one of the Top 30 most powerful women in Indian business by Business Today. and features in the coveted ‘BT Hall of Fame’ for being a consistent performer. In 2020, she was named the 13th most powerful woman in business by Fortune India. Business World has listed her among the 50 Most Influential Women in India.  Daruwala is also known for winning the President’s gold medal for coming in top in the India Company Secretary Exams.

She has served on the board of directors of key ICICI group companies, ICICI Lombard General Insurance and ICICI Securities; and was also on the board of JSW Steel for almost eight years.

Dinesh Kumar Khara, Chairman, State Bank of India

Chairman of the State Bank of India, Dinesh Kumar Khara assumed charge on October 7, 2020. Prior to this, he was the MD and CEO of SBI Funds Management Pvt. Limited (SBIMF).

Khara oversees the International Banking book, Corporate Banking book and Treasury operations of the Bank. Additionally, he supervises the businesses of Non-Banking subsidiaries of the Bank, engaged in diverse financial activities such as Asset Management, Life Insurance, General Insurance, Custodial Services, Primary Dealership, Investment Banking, Broking, Credit Cards, Pension Funds and Factoring services.

A Certified Associate of the Indian Institute of Bankers, Khara joined SBI in 1984 as a Probationary Officer. Since then he has held several key positions. He served as the MD (Global Banking & Subsidiaries), MD (Associates & Subsidiaries), MD & CEO (SBI Mutual Funds) and Chief General Manager – Bhopal Circle.

He was also posted in SBI, Chicago, for an overseas assignment. As Managing Director, he led the International Banking Group, Corporate Banking and Global Treasury Operations, as well as the non-banking subsidiaries of the Bank — SBI Cards, SBIMF, SBI Life Insurance and SBI General Insurance, etc.

He executed the merger of five Subsidiary Banks of SBI and Bhartiya Mahila Bank with SBI. Additionally, he headed the Risk, IT and Compliance functions of the bank at various points.

Sanjeev Mehta, Managing Director, Hindustan Unilever Limited

Chairman and Managing Director of India’s largest Fast Moving Consumer Goods (FMCG) company Hindustan Unilever Limited, Mehta started his career in 1983 with Union Carbide.

Mehta was a part of the crisis management team that worked on the Bhopal Gas tragedy in 1984, and since then he is known to start most meetings by reviewing the safety agenda.

A chartered accountant from the Institute of Chartered Accountants of India, Mehta became the CEO and MD of Hindustan Unilever in October 2013, and in June 2018 was appointed as the chairman and MD. Under him, HUL has taken on and expanded several initiatives that have a far-reaching societal and environmental impact.

Mehta also heads Unilever’s business in South Asia, as cluster president encompassing businesses in India, Pakistan, Bangladesh, Sri Lanka and Nepal. He is a member of the Unilever Leadership Executive, its global executive board.

Anish Shah, Managing Director & CEO, Mahindra Group

Anish Shah is the Managing Director and Chief Executive Officer of the Mahindra Group. He joined Mahindra Group as president, special projects, in 2014 and has been the MD, CEO, Member of the Group Executive Board and Additional Director of Mahindra & Mahindra since.

He served as the President and CEO of GE Capital India from 2009-2014, where he led the transformation of the business, including a turnaround of its SBI Card joint venture. His career at GE spanned 14 years, during which he held several leadership positions at GE Capital’s US and global units.

Shah has worked closely with all of the Group’s businesses on key strategic initiatives, built capabilities such as digitization and data sciences, and enabled synergies across group companies.

TV Narendran, Managing Director & CEO, Tata Steel 
Leading business executive TV Narendran is currently the global CEO and Managing Director of Tata Steel, one of the largest steel producers in the world. Before being appointed as MD of Tata Steel India and South East Asia on November 1, 2013, Narendran served as the Vice President, Safety and Flat Products Divisions, Tata Steel.
He is currently on the Boards of Tata Steel Limited, Tata Steel Europe, CEDEP, XLRI and World Steel Association. Narendran served as the President of Confederation of Indian Industry for the year 2021-22.
A mechanical engineer from the National Institute of Technology (NIT) Trichy, and MBA from the Indian Institute of Management (IIM) Calcutta, Narendran has over 32 years of experience in the Mining and Metals industry.

Prabha Narsimhan, Managing Director & CEO

Managing Director and Chief Executive Officer of Colgate-Palmolive (India) Limited, a leading subsidiary of the Colgate-Palmolive Company, Prabha Narsimhan has nearly 25 years of rich and varied experience in Customer Development, Consumer Marketing and Innovation across geographies and multiple categories, including Home Care, Foods, Personal & Skin Care.

She took over as the MD & CEO of Colgate-Palmolive in September 2022, after the former CEO Ram Raghavan took over a role at the parent company.

Narasimhan joined HUL in January 2006 as a regional marketing manager before becoming a regional brand director for the company’s Lipton & Brooke Bond brands the next year, as per her LinkedIn profile.

An Indian Institute of Management-Bangalore alumni, she rose through the ranks in HUL in over 15 years to become executive director for homecare and vice-president, homecare, for Unilever, South Asia. Before HUL, she had a brief stint at Madura Garments as general manager, strategy.

V Vaidyanathan, Managing Director & CEO, IDFC First Bank

V Vaidyanathan is the first Managing Director and CEO of IDFC First Bank, after he agreed to merge Capital First with IDFC Bank in December 2018 in order to secure a commercial banking license.

With an experience of over two decades in financial services in India, Vaidyanathan was heading ICICI Prudential Life Insurance and served on the Board of ICICI Bank before joining IDFC Bank as MD & CEO. He was also the Chairman of ICICI Home Finance Co Ltd, and served on the Board of ICICI Lombard General Insurance Company, CIBIL – India’s first Credit Bureau, and SMERA- SIDBI’s Credit Rating Agency.

Adar Poonawalla, CEO, Serum Institute of India 

Adar Poonawalla is the CEO of the world’s largest vaccine manufacturer, Serum Institute of India, founded in 1966. He took over as the CEO in 2011 and since then has continued to lead the expansion of SII, developing affordable vaccines for global outbreaks – most currently the COVID-19 vaccine – and for preventable diseases, particularly in low- and middle-income countries.

SII has produced and distributed over 280 million doses of the Covid-19 vaccine to 70 countries (as of June 2021) and is continuing to increase production month-on-month. Many new vaccines such as Rotavirus and Pneumococcal have been produced in his tenure.

Besides, he is the founder of Poonawalla Fincorp, a fast-growing digital non-banking financial company, established in 2019 and headquartered in Pune. Adar is a former board member of GAVI, the Vaccine Alliance focused on helping vaccinate the world’s children against deadly and debilitating infectious diseases.

Adar has been recognised with a number of accolades over the years, most recently Fortune’s Greatest Leaders (2021), Economic Times Entrepreneur of the Year (2021), Hurun National Icon of Philanthropy (2019), Indian of the Year – CSR Category (2020), Forbes India Leadership Awards GenNext Entrepreneur (2018) and CNBC Asia’s Corporate Social Responsibility (2018).

Rajeev Memani, Chairman & Regional Managing Partner, EY India  

Rajiv Memani  is the Chairman and Regional Managing Partner of EY India. He is also a member of EY’s Global Executive Board and Chairman of EY’s Global Emerging Markets Committee.

Rajiv is currently affiliated with prominent business and industry associations. He is a member of the National Council of the Confederation of Indian Industry (CII), in addition to being the Chairman of its National Committee on Tax. He is also a past president of the India Chapter of the International Chamber of Commerce (ICC).

In 2013, Rajiv was appointed on the Global Executive Board of EY as the Chairman of the Global Emerging Markets Committee, in addition to his role as the Chairman and Regional Managing Partner, EY India. In his role as the Chairman of Global Emerging Markets committee, Rajiv’s responsibilities include connecting emerging markets with developed markets as well as recommending investment plans for these markets.

Also Read: IBLA Jury meet: RBI policy to Budget 2023 – India’s most successful business leaders discuss the growth story

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

SII seeks inclusion of Covid jab Covovax in CoWIN portal as heterologous booster dose for adults

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII) wrote a letter to Union Health Ministry seeking the inclusion of its Covid vaccine Covovax in the CoWIN portal as a heterologous booster dose for adults.

Serum Institute of India has written to the Union Health Ministry seeking the inclusion of its Covid vaccine Covovax in the CoWIN portal as a heterologous booster dose for adults, official sources said on Wednesday.

The letter was written by Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII), they said.

National Technical Advisory Group on Immunisation (NTAGI) is likely to hold a meeting soon to decide on the matter.

The Drug Controller General of India (DCGI) on January 16 approved market authorisation for Covovax as a heterologous booster dose for adults who have been administered two doses of either Covishield or Covaxin.

Also Read: Imports of COVID-19 vaccines exempted from customs duty till March 31

Its approval was based on recommendations by the subject expert committee (SEC) of the Central Drugs Standard Control Organisation.

The DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and also in children aged seven to 11 years on June 28 last year subject to certain conditions.

Covovax is manufactured through technology transfer from Novavax.

It has been approved by the European Medicines Agency for conditional marketing authorization and was granted emergency-use listing by the World Health Organization (WHO) on December 17, 2021.

In August 2020, US-based vaccine maker Novavax Inc. had earlier announced a licence agreement with the SII for the development and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate in India and low-and-middle-income countries.

Also Read: DCGI approves market authorisation for Covovax as COVID booster dose

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Posing as Adar Poonawalla, scammers steal Rs 1 crore from Serum Institute of India, seven arrested

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Seven people have been arrested for allegedly using the image of Serum Institute of India CEO Adar Poonawalla and getting a director of the leading vaccine-producing firm to transfer Rs 1.01 crore to various bank accounts, Pune police said on Friday.

Seven people have been arrested for allegedly using the image of Serum Institute of India CEO Adar Poonawalla and getting a director of the leading vaccine-producing firm to transfer Rs 1.01 crore to various bank accounts, Pune police said on Friday.

As per the First Information Report registered with Bundgarden police station in the second week of September, the accused had used Poonawalla’s image in a Whatsapp account and sent messages about money transfer to Satish Deshpande, one of the directors of the firm, an official said.

Believing the messages were from Poonawalla, the director transferred Rs 1.01 crore of the firm’s funds to eight bank accounts mentioned in the Whatsapp conversation, he said.

Also Read: Amitabh Bachchan seeks protection of his personality rights, says ‘going on for a while’

“The eight bank accounts belonged to eight persons. Seven of these persons have been arrested from different states, while the hunt is on for the main accused. We have seized 40 accounts into which money from these eight accounts was transferred,” said Zone II Deputy Commissioner of Police Smarthna Patil.

“We have managed to confiscate Rs 13 lakh in these accounts. The accused are B.Tech and B.Sc graduates hailing from Bihar, Uttar Pradesh, Madhya Pradesh and Andhra Pradesh. One of them works in a commercial bank,” the DCP added.

Also Read: Government convenes all-party meeting on December 6 ahead of winter session

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Govt panel recommends emergency approval for SII’s Covovax for 7-11 year olds

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

“The Subject Expert Committee (SEC) on COVID-19 of the CDSCO deliberated on the EUA application of SII and recommended granting emergency use authorisation for Covovax for children aged 7 to 11 years,” an official source said.

An expert panel of India’s central drug authority on Friday recommended granting emergency use authorisation to Serum Institute’s Covovax for children aged 7 to 11 years, official sources said.

The recommendation has been sent to the Drugs Controller General of India (DCGI) for final approval. The application for emergency use authorisation was submitted by Prakash Kumar Singh, director (government and regulatory affairs) at Serum Institute of India (SII) on March 16.

“The Subject Expert Committee (SEC) on COVID-19 of the CDSCO deliberated on the EUA application of SII and recommended granting emergency use authorisation for Covovax for children aged 7 to 11 years,” an official source said.

Also Read: Covid-19 vaccines prevented over 42 lakh deaths in India in 2021: Lancet study

The expert panel in its last meeting in April had sought more data from the Pune-based firm over the application.

The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12 to 17 years age group subject to certain conditions on March 9.

The country began inoculating children aged 12-14 from March 16. The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase. Vaccination of frontline workers started from February 2 last year.

The next phase of COVID-19 vaccination commenced on March 1 last year for people over 60 years of age and those aged 45 and above with specified co-morbid conditions. India launched vaccination for all people aged more than 45 years from April 1 last year.

Also Read: Corbevax vaccine gets DGCI nod as a heterologous COVID-19 booster dose for adults

The government then decided to expand its vaccination drive by allowing everyone above 18 years of age to be inoculated against the viral disease from May 1 last year. The next phase of vaccination commenced from January 3 for adolescents in the age group of 15-18 years.

India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10. Precaution does of COVID-19 vaccines for all aged above 18 years began at private vaccination centres from April 10.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Serum Institute to launch indigenously designed vaccine for cervical cancer soon

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

At present, India sources HPV vaccines Gardasil and Cervarix from foreign manufacturers Merck and Glaxo Smithkline. Serum Institute of India’s entry into the space is likely to bring down prices of the vaccine that costs Rs 2,000-3,000 per dose

The subject expert committee (SEC) under the Drugs Controller General of India (DCGI) will review the first indigenously designed quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer by the Serum Institute of India (SII) today.

This takes the vaccine a step closer to being inducted into the country’s immunisation programme, a move that could aid in preventing thousands of cervical cancer cases every year.

“The SEC will review the SII’s data, and if everything goes well, the vaccine will be approved,” Economic Times quoted sources as saying.

ALSO READ: CCI approves Serum Institute Life Sciences-Biocon Biologics deaL

At present, India sources HPV vaccines Gardasil and Cervarix from foreign manufacturers Merck and Glaxo Smithkline. The Serum Institute of India’s entry into the space is likely to bring down prices of the vaccine that costs Rs 2,000-3,000 per dose.

The market authorisation application for the qHPV vaccination was filed with the drug regulator by Prakash Kumar Singh, director of government and regulatory affairs at the Pune-based Serum Institute of India, on June 8.

The application states that the vaccine Cervavac has shown significant antibody response in both dose and age categories against all targeted HPV types.

Meanwhile, the Serum Institute of India has started making preparations as the manufacturing process for qHPV takes around four to five months, Business Standard had reported earlier.

The vaccine is likely to hit the market by the end of 2022, ANI reported. Its induction into the national immunisation programme will boost India’s fight against cervical cancer, which is the fourth most common cancer in women. The country reports 80,000-90,000 cases of cervical cancer every year.

According to the World Health Organisation, the vaccine is already being given to girls in over 100 countries.

The Serum Institute of India is also believed to have made a presentation before India’s apex immunisation body, the National Technical Advisory Group on Immunisation (NTAGI), on the usefulness of this vaccine. The NTAGI will take a decision on vaccine’s introduction in the immunisation programme at a meeting later this month, Economic Times reported

ALSO READ:  Serum Institute of India seeks government nod to manufacture & stockpile qHPV vaccine against cervical cancer

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Serum Institute’s skin test for latent TB diagnosis gets DGCI nod

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Pune-based firm Mylab has partnered with SII for the Cy-Tb kit. India is committed to eliminate tuberculosis by 2025, five years ahead of the target set by Sustainable Development Goals 2030.

Drug regulator DGCI has granted market authorisation to the Serum Institute of India’s Cy-Tb kit for people aged 18 years and above. The kit can be used for skin test to diagnose latent tuberculosis, official sources said on Tuesday. The approval comes following recommendations by the subject expert committee (SEC), which had reviewed the findings of the study conducted by the Indian Council of Medical Research (ICMR).

The Drugs Controller General of India (DGCI) gave its approval on Monday. Director, Government and Regulatory Affairs at Serum Institute of India (SII), Prakash Kumar Singh, had submitted an application to the DGCI seeking market authorisation for the kit.

Also read: Serum Institute seeks emergency use authorisation for its rBCG tuberculosis vaccine

Pune-based firm Mylab has partnered with the SII for this kit, an official source said. “Under the leadership of our CEO Adar Poonawalla our firm (SII) is committed to make available a made in India, next generation, highly cost effective skin test for diagnosis of Tuberculosis infection (Cy-Tb). The availability of Cy-Tb will play a crucial role in making India TB free and will also be in line with our Prime Minister’s vision of Making in India for the world,” an official source quoted Singh as having said in the application.

India is committed to eliminate tuberculosis by 2025, five years ahead of the target for TB set by Sustainable Development Goals 2030.

Also read: View: The 3Cs to solve the TB Conundrum

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Serum COVID vaccine Covovax now available for 12-17 age group at private centres

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

As per official sources, children aged 12 to 17 can now acquire the Serum Institute’s coronavirus vaccine Covovax at private clinics if a request is made on the CoWIN portal.

Children aged 12 to 17 years can now get the Serum Institute’s coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday. A dose of Covovax will cost Rs 900 plus GST, in addition to hospital service charge of Rs 150, they told PTI.

The move followed the recommendation of the National Technical Advisory Group on Immunisation (NTAGI) that the COVID-19 jab can be administered in the age group of 12-17 years. Serum Institute of India (SII) Director for Government and Regulatory Affairs Prakash Kumar Singh had written to the Union Health Ministry recently, requesting for Covovax’s inclusion in the immunisation drive for children aged 12 to 17 years.

Also read: Gap between 2nd dose of COVID vaccine, precaution dose to be reduced to 6 months soon, says report

In his letter, Singh had stated that the Pune-based firm wanted to provide Covovax to private hospitals at a per-dose rate of Rs 900 plus Goods and Services Tax (GST). “Those aged 12-17 age group can now opt for Covovax shot at private hospitals. The provision for the same has been made at the CoWIN portal on Monday evening,” an official source told PTI.

India’s drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 last year and in the 12-17 age group, subject to certain conditions, on March 9. Currently, children aged 12 to 14 years are vaccinated with Biological E’s intramuscular vaccine Corbevax, while those in the 15-18 age group are being administered Bharat Biotech’s Covaxin at government vaccination centres.

Also read: SII to give free Covishield vials to pvt vaccination centres to compensate for price difference

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?